Kelun-Biotech wins China IND clearance for SKB565 in advanced solid tumors

PUBT · 1d ago
Kelun-Biotech wins China IND clearance for SKB565 in advanced solid tumors
  • Sichuan Kelun-Biotech received NMPA drug regulator clearance to start clinical trials of SKB565 in advanced solid tumors.
  • SKB565 is a dual-payload antibody-drug conjugate built on the OptiDC platform, pairing a toxin payload with an immunomodulator.
  • The decision moves Kelun-Biotech’s first dual-payload ADC into the clinic, supporting its “ADC + IO” development strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260727-12257620), on July 27, 2026, and is solely responsible for the information contained therein.